Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer Stage III
  3. NCT03236883

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer — HST  

Pancreatic Cancer Stage IV Clinical Trial

Official title:
Phase I Study of Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer

Clinical Trial Summary

To evaluate the safety and efficacy of non-myeloablative hematopoietic stem cell transplantation in the treatment of pancreatic cancer.

Clinical Trial Description

Allogeneic hematopoietic stem cell transplantation has been successfully used for the treatment of hematopoietic malignancy. In recent years, non-myeloablative hematopoietic stem cell transplantation (NST) has been introduced to treat solid tumors due to the Graft-versus tumor effect. In this study, the investigators try to evaluate the safety and efficacy of NST in the treatment of unresectable pancreatic cancer patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03236883
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact He Ren, MD,PHD
Phone 022-23340123-3073
Email renhe@tjmuch.com
Status Recruiting
Phase Phase 1
Start date April 2016
Completion date April 2019
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03252808 - Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer. Phase 1
Suspended NCT03697564 - Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). Phase 2
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06017284 - Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer Phase 3
Recruiting NCT04674956 - A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT03412799 - Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Phase 1
Completed NCT04181645 - SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer N/A
Withdrawn NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours Phase 1
Recruiting NCT04150042 - SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells Phase 1
Recruiting NCT04628806 - Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
Recruiting NCT02981641 - IORT Versus CCRT for Pancreatic Cancer N/A
Completed NCT04953962 - Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer Phase 2
Recruiting NCT05254171 - Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Phase 2/Phase 3
Recruiting NCT04406831 - The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
No longer available NCT04137822 - Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer